摘要
目的探讨苯扎贝特联合熊去氧胆酸治疗原发性胆汁性肝硬化的临床效果。方法选取2015年7月至2018年7月沈阳医学院附属中心医院收治的67例原发性胆汁性肝硬化患者作为研究对象,按治疗方法不同分为观察组(35例)与对照组(32例)。对照组予以熊去氧胆酸治疗,观察组在对照组基础上加用苯扎贝特治疗。比较两组患者治疗前后肝功能、T淋巴细胞亚群水平变化以及治疗后肝脏弹力硬度。结果治疗前,两组患者各项肝功能指标比较,差异无统计学意义(P>0.05);治疗后,两组患者的碱性磷酸酶(ALP)、谷丙转氨酶(ALT)、天冬氨酸转氨酶(AST)和总胆红素(TBil)均明显下降,且观察组患者各项指标均低于对照组,差异有统计学意义(P<0.05)。治疗前,两组患者T淋巴细胞亚群水平比较,差异无统计学意义(P>0.05);治疗后,两组患者的CD4^+较治疗前明显下降,CD8^+明显升高,观察组患者各项指标均优于对照组,差异有统计学意义(P<0.05)。观察组与对照组患者治疗后的肝脏弹力硬度值分别为(8.3±1.4)kPa、(11.4±1.6)kPa,组间比较差异有统计学意义(P<0.05)。结论苯扎贝特联合熊去氧胆酸治疗原发性胆汁性肝硬化,能明显改善患者的肝功能、T淋巴细胞亚群水平。
Objective To exlpore the effects of Benzafibrate combined with ursodeoxycholic acid in the treatment of primary biliary cirrhosis.Method A total of 67 patients with primary biliary cirrhosis admitted to the Affiliated Central Hospital of Shenyang Medical College from July 2015 to July 2018 were selected as the study subjects.They were divided into observation group(35 cases)and control group(32 cases)according to different treatment methods.The control group was treated with ursodeoxycholic acid,while the observation group was treated with Benzafibrate on the basis of the control group.The changes of liver function,T lymphocyte subsets and liver elasticity and hardness before and after treatment were compared between the 2 groups.Result Before treatment,there was no significant difference in liver function between the 2 groups(P>0.05).After treatment,alkaline phosphatase(ALP),glutamate transaminase(ALT),aspartate transaminase(AST)and total bilirubin(TBil)in the 2 groups were significantly decreased,and the indexes in the observation group were lower than those in the control group.There was significant difference between the 2 groups(P<0.05).Before treatment,there was no significant difference in T lymphocyte subsets between the 2 groups(P>0.05).After treatment,CD4^+decreased significantly and CD8^+increased significantly in the two groups.The indexes of the observation group were better than those of the control group,and the difference was statistically significant(P<0.05).The elastic hardness values of liver in the observation group and the control group after treatment were(8.3±1.4)kPa and(11.4±1.6)kPa,respectively.There were significant differences between the 2 groups(P<0.05).Conclusion Benzafibrate combined with ursodeoxycholic acid in the treatment of primary biliary cirrhosis can significantly improve the liver function and T lymphocyte subsets in patients with primary biliary cirrhosis.
作者
姜晗
JIANG Han(Department of Gastroenterology,Affiliated Central Hospital of Shenyang Medical College,Shenyang 110024,China)
出处
《中国药物经济学》
2019年第8期113-115,119,共4页
China Journal of Pharmaceutical Economics
